Heart stent firms may be hit by unfavourable study showing drugs as good – and cheaper – in stable patients
This article was originally published in Clinica
Executive Summary
Drug treatment for stable heart failure patients is just as good as stenting, and works out cheaper, a new study has suggested. The findings could have an unfavourable impact on sales of stent companies including Abbott, Boston Scientific, Medtronic and Johnson & Johnson.